

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound selected from the group consisting of N-[4-(2-Hydroxycarbamoylvinyl)benzyl]-4-pyrrolidin-1-ylbenzamide, and 4-Dimethylamino-N-[4-(2-hydroxycarbamoylvinyl)benzyl]benzamide; or a pharmaceutically acceptable salt thereof.
2. (Original) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable excipient or diluent.
3. (Currently Amended) A method of treating ~~cancer~~ breast cancer, lung cancer, or stomach cancer comprising administering the compound according to claim 1 to a patient.
4. (Canceled)
5. (Currently Amended) A method of inhibiting histone deacetylase (HDAC) activity in at least one breast cancer, lung cancer, or stomach cancer cell comprising providing the compound according to claim 1 to said at least one breast cancer, lung cancer, or stomach cancer cell.
6. (Canceled)